Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
EJNMMI Research
Published in: EJNMMI Research 1/2021

Open Access 01-12-2021 | Lymphoma | Original research

Semi-quantitative measurements of chemokine receptor 4-targeted 68Ga-pentixafor PET/CT in response assessment of Waldenström macroglobulinemia/lymphoplasmacytic lymphoma

Authors: Qingqing Pan, Xinxin Cao, Yaping Luo, Jian Li, Fang Li

Published in: EJNMMI Research | Issue 1/2021

Login to get access

Abstract

Purpose

68Ga-pentixafor PET/CT was reported to have a high sensitivity in detecting tumor involvement of Waldenström macroglobulinemia/lymphoplasmacytic lymphoma (WM/LPL) in our previous study. We aimed to further investigate the semi-quantitative measurements of 68Ga-pentixafor PET/CT in response assessment in WM/LPL.

Methods

Fifteen patients with WM/LPL were recruited in a prospective cohort study and underwent both 68Ga-pentixafor and 18F-FDG PET/CT at baseline and post-treatment. PET/CT-based responses were analyzed with semi-quantitative assessments of metabolic tumor volume (MTV) and total lesions glycolysis/uptake (TLGFDG and TLUCXCR4), and the correlation between PET/CT-based response and clinical response, monoclonal protein and IgM response was analyzed.

Results

After chemotherapy, 5 patients had complete response or very good partial response, 8 had partial response or minimal response and 2 had progressive disease. In quantitative analysis, 68Ga-pentixafor PET/CT-based response (measured in ∆TLUCXCR4%, ∆MTVCXCR4%, ∆SUVpeak%) showed a significant direct correlation with clinical response, monoclonal protein and IgM response (p < 0.01). However, 18F-FDG PET/CT-based response was independent from clinical response (p > 0.05).

Conclusions

The semi-quantitative measurements of 68Ga-pentixafor PET/CT outperformed 18F-FDG PET/CT in response assessment of WM/LPL.
Appendix
Available only for authorised users
Literature
1.
Johnson SA, Birchall J, Luckie C, Oscier DG, Owen RG. Guidelines on the management of Waldenström macroglobulinaemia. Br J Haematol. 2006;132:683–97.CrossRef
2.
Weber D, Treon SP, Emmanouilides C, Branagan AR, Byrd JC, Bladé J, et al. Uniform response criteria in Waldenstrom’s macroglobulinemia: consensus panel recommendations from the second international workshop on Waldenstrom’s Macroglobulinemia. Semin Oncol. 2003;30:127–31.CrossRef
3.
Owen RG, Kyle RA, Stone MJ, Rawstron AC, Leblond V, Merlini G, et al. Response assessment in Waldenström macroglobulinaemia: update from the VIth international workshop. Br J Haematol. 2013;160:171–6.CrossRef
4.
Dimopoulos MA, Kastritis E, Owen RG, Kyle RA, Landgren O, Morra E, et al. Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders: IWWM-7 consensus. Blood. 2014;124:1404–11.CrossRef
5.
Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Lister TA. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32:3059–68.CrossRef
6.
Barrington SF, Mikhaeel NG, Kostakoglu L, Meignan M, Hutchings M, Mueller SP, et al. Role of imaging in the staging and response assessment of lymphoma: consensus of the international conference on Malignant Lymphomas Imaging Working Group. J Clin Oncol. 2014;32:3048–58.CrossRef
7.
Banwait RORK, Campigotto F, et al. The role of 18F-FDG PET/CT imaging in Waldenstrom macroglobulinemia. Am J Hematol. 2011;86:567–72.CrossRef
8.
Teicher BA, Fricker SP. CXCL12 (SDF-1)/CXCR4 pathway in cancer. Clin Cancer Res. 2010;16:2927–31.CrossRef
9.
Ngo HT, Leleu X, Lee J, Jia X, Melhem M, Runnels J, et al. SDF-1/CXCR4 and VLA-4 interaction regulates homing in Waldenstrom macroglobulinemia. Blood. 2008;112:150–8.CrossRef
10.
Hunter ZR, Yang G, Xu L, Liu X, Castillo JJ, Treon SP. Genomics, signaling, and treatment of Waldenstrom macroglobulinemia. J Clin Oncol. 2017;35:994–1001.CrossRef
11.
Luo Y, Cao X, Pan Q, Li J, Feng J, Li F. (68)Ga-Pentixafor PET/CT for imaging of chemokine receptor 4 expression in Waldenstrom macroglobulinemia/lymphoplasmacytic lymphoma: comparison to (18)F-FDG PET/CT. J Nucl Med. 2019;60:1724–9.CrossRef
12.
Luo YPQ, Feng J, et al. Chemokine receptor CXCR4-targeted PET/CT with 68Ga-pentixafor shows superiority to 18F-FDG in a patient with Waldenstrom macroglobulinemia. Clin Nucl Med. 2018;43:548–50.CrossRef
13.
Pan Q, Luo Y, Zhang Y, Chang L, Li J, Cao X, et al. Preliminary evidence of imaging of chemokine receptor-4-targeted PET/CT with [(68)Ga]pentixafor in non-Hodgkin lymphoma: comparison to [(18)F]FDG. EJNMMI Res. 2020;10:89.CrossRef
14.
Pan Q, Luo Y, Qian M. Detection of residual tumor with 68Ga-pentixafor PET/CT in a patient with Waldenström macroglobulinemia and concurrent John Cunningham virus-related progressive multifocal leukoencephalopathy. Clin Nucl Med. 2020;45:792–4.CrossRef
15.
Pan Q, Cao X, Luo Y, Li J, Li F. Chemokine receptor 4-targeted 68Ga-pentixafor PET/CT in response assessment of Waldenström macroglobulinemia/lymphoplasmacytic lymphoma: comparison to 18F-FDG PET/CT. Clin Nucl Med. 2021;46:732–7.PubMed
16.
Krak NC, Boellaard R, Hoekstra OS, Twisk JW, Hoekstra CJ, Lammertsma AA. Effects of ROI definition and reconstruction method on quantitative outcome and applicability in a response monitoring trial. Eur J Nucl Med Mol Imaging. 2005;32:294–301.CrossRef
17.
Boellaard R, Delgado-Bolton R, Oyen WJ, Giammarile F, Tatsch K, Eschner W, et al. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2015;42:328–54.CrossRef
18.
Morel P, Duhamel A, Gobbi P, Dimopoulos MA, Dhodapkar MV, McCoy J, et al. International prognostic scoring system for Waldenstrom macroglobulinemia. Blood. 2009;113:4163–70.CrossRef
19.
Treon SP, Xu L, Yang G, Zhou Y, Liu X, Cao Y, et al. MYD88 L265P somatic mutation in Waldenstrom’s macroglobulinemia. N Engl J Med. 2012;367:826–33.CrossRef
20.
Treon SP, Yang G, Hanzis C, Ioakimidis L, Verselis SJ, Fox EA, et al. Attainment of complete/very good partial response following rituximab-based therapy is an important determinant to progression-free survival, and is impacted by polymorphisms in FCGR3A in Waldenstrom macroglobulinaemia. Br J Haematol. 2011;154:223–8.CrossRef
21.
Treon SP, Branagan AR, Ioakimidis L, Soumerai JD, Patterson CJ, Turnbull B, et al. Long-term outcomes to fludarabine and rituximab in Waldenström macroglobulinemia. Blood. 2009;113:3673–8.CrossRef
22.
Treon SP, Ioakimidis L, Soumerai JD, Patterson CJ, Sheehy P, Nelson M, et al. Primary therapy of Waldenström macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05–180. J Clin Oncol. 2009;27:3830–5.CrossRef
23.
Ghobrial IM, Fonseca R, Greipp PR, Blood E, Rue M, Vesole DH, et al. Initial immunoglobulin M “flare” after rituximab therapy in patients diagnosed with Waldenstrom macroglobulinemia: an Eastern Cooperative Oncology Group Study. Cancer. 2004;101:2593–8.CrossRef
24.
Leblond V, Kastritis E, Advani R, Ansell SM, Buske C, Castillo JJ, et al. Treatment recommendations from the eighth international workshop on Waldenstrom’s macroglobulinemia. Blood. 2016;128:1321–8.CrossRef
25.
Lapa C, Herrmann K, Schirbel A, Hanscheid H, Luckerath K, Schottelius M, et al. CXCR4-directed endoradiotherapy induces high response rates in extramedullary relapsed multiple myeloma. Theranostics. 2017;7:1589–97.CrossRef
26.
Lapa C, Luckerath K, Kircher S, Hanscheid H, Grigoleit GU, Rosenwald A, et al. Potential influence of concomitant chemotherapy on CXCR4 expression in receptor directed endoradiotherapy. Br J Haematol. 2019;184:440–3.CrossRef
Metadata
Title
Semi-quantitative measurements of chemokine receptor 4-targeted 68Ga-pentixafor PET/CT in response assessment of Waldenström macroglobulinemia/lymphoplasmacytic lymphoma
Authors
Qingqing Pan
Xinxin Cao
Yaping Luo
Jian Li
Fang Li
Publication date
01-12-2021
Publisher
Springer Berlin Heidelberg
Published in
EJNMMI Research / Issue 1/2021
Electronic ISSN: 2191-219X
DOI
https://doi.org/10.1186/s13550-021-00852-0

Other articles of this Issue 1/2021

EJNMMI Research 1/2021 Go to the issue

Letter to the Editor

More fat, less migration: breast density as a predictor of sentinel lymph node non-visualization in breast cancer

Review

There is a world beyond αvβ3-integrin: Multimeric ligands for imaging of the integrin subtypes αvβ6, αvβ8, αvβ3, and α5β1 by positron emission tomography

Original research

Post-reconstruction enhancement of [18F]FDG PET images with a convolutional neural network

Original research

Short-duration dynamic [18F]DCFPyL PET and CT perfusion imaging to localize dominant intraprostatic lesions in prostate cancer: validation against digital histopathology and comparison to [18F]DCFPyL PET/MR at 120 minutes

Original research

Detection and therapy of neuroblastoma minimal residual disease using [64/67Cu]Cu-SARTATE in a preclinical model of hepatic metastases

Original research

PSMA-ligand uptake can serve as a novel biomarker in primary prostate cancer to predict outcome after radical prostatectomy